C4X Discovery Holdings plc
(“C4XD”, “C4X Discovery” or the “Company”)
Clive Dix appointed to the UK Vaccine Taskforce
Government’s taskforce to lead UK efforts to deliver a COVID-19 vaccine
5 June 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to confirm that Clive Dix, Chief Executive Officer of C4XD has been appointed a member and Deputy Chair of the Steering Board of the UK Vaccine Taskforce, the group set up by the Government’s Chief Scientific Adviser, Deputy Chief Medical Officer, Business Secretary and Health Secretary to lead UK efforts to find and manufacture a COVID-19 vaccine.
Clive remains committed to delivering C4XD’s strategy and this appointment will not impact his day-to-day role as CEO.
Eva-Lotta Allan, Chairman of C4XD, commented:
“We are very proud that Clive has been appointed to this important and prestigious taskforce. COVID-19 has had such a devastating impact not only in the UK, but across the world. The development of a vaccine is vital to saving lives and enabling everyone to get back to normality. The taskforce has been assembled to bring together the brightest minds in the scientific industry to deliver a COVID-19 vaccine that will be effective and accessible. Clive’s rich and diverse experience, both as a scientist and from managing pharmaceutical companies, means he understands what is required to bring a product like this to market. This will be invaluable to the taskforce as it works quickly to find a solution to the COVID-19 pandemic.”
C4X Discovery Holdings plc
Mo Noonan, Communications+44 (0)7876 444 977
Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700
The Taskforce is supporting efforts to develop a COVID-19 vaccine as soon as possible by providing industry and research institutions with the resources and support needed. This includes working with regulators and scaling up manufacturing, so that when a vaccine is identified, it can be produced quickly and at scale.
The Bioindustry Association is working closely with the Taskforce, bringing together a whole range of businesses keen to use their expertise to mass-produce vaccines, as soon as one is ready.
C4X Discovery (“C4XD”) is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, neurodegeneration, oncology and addictive disorders. Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for a commercial deal and to date we have successfully out-licensed two programmes with one candidate in clinical development.
We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio. For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery .
This website uses 'cookies' to give you the best most relevant experience. To continue you have to agree to our use of cookies policy and how and why we use cookies.
You can change which cookies are set at any time and find out more about them by reading our privacy policy.